Logo image of ALINT.PA

INTEGRAGEN (ALINT.PA) Stock Fundamental Analysis

EPA:ALINT - Euronext Paris - Matif - FR0010908723 - Common Stock - Currency: EUR

0.518  +0.01 (+1.57%)

Fundamental Rating

2

ALINT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 65 industry peers in the Biotechnology industry. Both the profitability and financial health of ALINT have multiple concerns. ALINT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ALINT has reported negative net income.
ALINT had negative earnings in 4 of the past 5 years.
ALINT had a negative operating cash flow in each of the past 5 years.
ALINT.PA Yearly Net Income VS EBIT VS OCF VS FCFALINT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2023 0 -500K -1M -1.5M -2M

1.2 Ratios

The Return On Assets of ALINT (-0.48%) is better than 67.69% of its industry peers.
ALINT has a better Return On Equity (-1.58%) than 70.77% of its industry peers.
Industry RankSector Rank
ROA -0.48%
ROE -1.58%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALINT.PA Yearly ROA, ROE, ROICALINT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

Looking at the Gross Margin, with a value of 64.61%, ALINT is in the better half of the industry, outperforming 63.08% of the companies in the same industry.
In the last couple of years the Gross Margin of ALINT has grown nicely.
The Profit Margin and Operating Margin are not available for ALINT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.01%
GM growth 5Y2.3%
ALINT.PA Yearly Profit, Operating, Gross MarginsALINT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2023 0 20 -20 40 -40 60

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ALINT has been increased compared to 1 year ago.
Compared to 5 years ago, ALINT has more shares outstanding
Compared to 1 year ago, ALINT has an improved debt to assets ratio.
ALINT.PA Yearly Shares OutstandingALINT.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2023 2024 2M 4M 6M
ALINT.PA Yearly Total Debt VS Total AssetsALINT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2023 2024 2M 4M 6M 8M

2.2 Solvency

An Altman-Z score of 2.25 indicates that ALINT is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALINT's Altman-Z score of 2.25 is fine compared to the rest of the industry. ALINT outperforms 67.69% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that ALINT is not too dependend on debt financing.
ALINT's Debt to Equity ratio of 0.22 is fine compared to the rest of the industry. ALINT outperforms 61.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 2.25
ROIC/WACCN/A
WACCN/A
ALINT.PA Yearly LT Debt VS Equity VS FCFALINT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2023 2024 1M 2M 3M

2.3 Liquidity

ALINT has a Current Ratio of 1.53. This is a normal value and indicates that ALINT is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ALINT (1.53) is worse than 61.54% of its industry peers.
ALINT has a Quick Ratio of 1.45. This is a normal value and indicates that ALINT is financially healthy and should not expect problems in meeting its short term obligations.
ALINT has a Quick ratio of 1.45. This is in the lower half of the industry: ALINT underperforms 60.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.45
ALINT.PA Yearly Current Assets VS Current LiabilitesALINT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2023 2024 2M 4M 6M 8M

More info and screens

2

3. Growth

3.1 Past

ALINT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
The Revenue for ALINT has decreased by -11.77% in the past year. This is quite bad
The Revenue has been growing by 13.43% on average over the past years. This is quite good.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-11.77%
Revenue growth 3Y13.13%
Revenue growth 5Y13.43%
Sales Q2Q%-24.96%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALINT.PA Yearly Revenue VS EstimatesALINT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2023 2M 4M 6M 8M 10M
ALINT.PA Yearly EPS VS EstimatesALINT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALINT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALINT.PA Price Earnings VS Forward Price EarningsALINT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALINT.PA Per share dataALINT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALINT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTEGRAGEN

EPA:ALINT (6/27/2025, 7:00:00 PM)

0.518

+0.01 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-20 2024-10-20
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.49M
Analysts86.67
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B 1.83
P/tB 1.83
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.64
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.48%
ROE -1.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.61%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.01%
GM growth 5Y2.3%
F-ScoreN/A
Asset Turnover1.77
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 1.45
Altman-Z 2.25
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.77%
Revenue growth 3Y13.13%
Revenue growth 5Y13.43%
Sales Q2Q%-24.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y57.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A